Tran Yvonne sold $1.1M of SDGR

Tran Yvonne (EVP, CLO & CPO) sold 32,000 shares of Schrodinger, Inc. (SDGR) at an average of $32.85 ($29.97–$33.11, $1.05M total) across 4 trades on 2026-11-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tran Yvonne
Published Nov 10, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SDGR
Bearish
medium confidence
Mentioned
$SDGR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SDGRBearishLow
01

Why it matters

The disclosed sale adds new information about insider holdings and may influence short‑term price action.

02

Market read

Insider sales are watched by traders for potential signals; this filing provides fresh data for SDGR.

03

What to watch

The 10b5‑1 plan may have been set months ago; the timing may not indicate current sentiment.

Relevance 5/10Novelty 4/10Timing: after‑market today

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

$SDGRBearishMedium confidence
Context

EVP and CLO Yvonne Tran sold 32,000 shares for $1.05M via a 10b5‑1 plan on 2026‑11‑09.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A senior executive sold over $1M of stock; such sales often prompt short‑term selling pressure.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No regional effect; confined to SDGR shareholders.

Limited global relevance.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect negative outlook.

Key entities

  • Schrodinger, Inc.

    Biophysics software company listed on NASDAQ under ticker SDGR.

  • Tran Yvonne

    Executive Vice President, Chief Legal Officer & Chief Procurement Officer at Schrodinger.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SDGRMed

Schrödinger (SDGR) Q3 2026 Earnings Call Transcript

Schrödinger (SDGR) reported Q3 2026 earnings, highlighting 17% ACV growth and 19% total revenue increase. Key drivers included broader adoption in pharmaceuticals, new product introductions like Bunsen, and growth in biotech and material science sectors. The company raised full-year guidance for ACV and drug discovery revenue. Financials included $44.7M in ACV, $64.5M in total revenue, and a net loss of $38M. Hosted software licensing grew to 45% of software revenue.

$SDGRMed

Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong

Schrodinger Inc (SDGR) reported Q3 2026 earnings with a widened net loss of $38M, despite revenue growth. The company raised guidance, citing strong ACV and customer confidence in its technology. Revenue growth is impacted by a transition to hosted licensing. Bunsen, a new product, is in early access, and material science adoption lags behind pharma/biotech. Drug discovery revenue is milestone-dependent, with intensifying competition in AI-driven molecular discovery.

$SDGRMed

Schrödinger Reports Third Quarter 2026 Financial Results

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Third Quarter 2026 Financial Results Third Quarter ACV of $45 Million, Representing 17% Growth Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial

$SDGRMed

SDGR Looks 19.2% Undervalued on GF Value™

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.